Literature DB >> 2177366

An in vitro approach to the kinetics of insulin antibodies in diabetic patients.

L T Ho1, L M Wang, T C Chang, T J Fung, J C Perng, Y F Liu, T Ho.   

Abstract

The purpose of this study is to evaluate the binding behavior of plasma insulin antibodies (Iab) in diabetic patients, by the following parameters: Incubation time, temperature, buffer pH, and Iab titer. We investigated the plasma insulin binding patterns of 12 insulin-treated diabetic patients, and they were separated as higher titer group (Iab = 51.9 +/- 7.28, n = 6) and lower titer group (Iab = 14.88 +/- 4.75, n = 6). The procedure was: (1) plasma samples were deinsulinized by 0.12N HCL, dextran coated charcoal suspension and 0.12N NaOH. (2) I-125 monoiodoinsulin was used to prevent artifacts resulting from variability in ligand binding due to excessive iodination, (3) separation of free and bound insulin was accomplished by rapid precipitation of hormone-antibody complex with polyethylene glycol, and (4) decanting the supernatants and counting the pellets in the automatic gamma counter. The data were obtained as the condition of incubation time, temperature, buffer pH, and Iab titer. The results obtained by the Scatchard analysis indicated that high temperature (39 degrees C vs 37 degrees C) in vitro would increase the free insulin levels and decrease the low affinity binding capacity (Q2-Q1) of Iab in patients with high titer of Iab (greater than 40%), whereas this phenomenon is not observed in patients with low affinity binding sites of Iab in patients with low titers of insulin antibodies (less than 20%).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2177366

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi (Taipei)        ISSN: 0578-1337


  1 in total

1.  A novel treatment of hyperinsulinemic hypoglycemia induced by insulin antibodies with alkali administration: a case report.

Authors:  Seiji Kobayashi; Houichi Amano; Yoshindo Kawaguchi; Takashi Yokoo
Journal:  J Med Case Rep       Date:  2019-03-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.